Embecta Corp. (NASDAQ:EMBC – Get Free Report) announced a quarterly dividend on Friday, August 9th, Zacks reports. Shareholders of record on Tuesday, August 27th will be given a dividend of 0.15 per share on Friday, September 13th. This represents a $0.60 dividend on an annualized basis and a yield of 4.29%. The ex-dividend date is Tuesday, August 27th.
Embecta has a payout ratio of 26.2% meaning its dividend is sufficiently covered by earnings. Analysts expect Embecta to earn $2.23 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 26.9%.
Embecta Trading Up 6.1 %
Shares of EMBC opened at $14.00 on Monday. Embecta has a twelve month low of $9.93 and a twelve month high of $19.79. The firm has a market capitalization of $807.38 million, a P/E ratio of 11.57 and a beta of 0.99. The firm’s 50-day moving average is $13.63 and its two-hundred day moving average is $13.14.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley reduced their price target on shares of Embecta from $13.00 to $12.00 and set an “underweight” rating on the stock in a report on Monday, July 15th.
View Our Latest Analysis on Embecta
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Read More
- Five stocks we like better than Embecta
- What is Forex and How Does it Work?
- 3 Surging Call Options and What They Mean for Investors
- What is a Death Cross in Stocks?
- Rate Cuts a Near Certainty: 3 Stocks You Might Have Missed
- What is a support level?
- Why These 2 Off-Price Retail Stocks Are Gaining Momentum in 2024
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.